Sanofi and Regeneron expand immunology alliance in deal worth up to $8bn
Sanofi and Regeneron have expanded their long-running immunology alliance with four next-generation antibody programmes in a deal worth up to $8 billion.
Regeneron will receive $1 billion upfront and could earn up to $7 billion in additional development, regulatory and commercial milestone payments.
The expanded partnership includes long-acting IL-13 and IL-4/IL-13 programmes and retains an equal sharing model for development costs, commercialisation costs and future profits.
Field | Content |
Article Type | Deals |
Companies | Sanofi; Regeneron |
Deal Type | Expanded global immunology research and development alliance |
Therapy Area | Immunology |
Programme Scope | Four next-generation long-acting antibody programmes |
Key Assets | REGN20423; long-acting IL-4xIL-13 bispecific and additional antibody programmes |
Technology/Modality | Monoclonal and bispecific antibodies |
Upfront Payment | $1 billion |
Potential Milestones | Up to $7 billion |
Potential Deal Value | Up to $8 billion |
Economics | Development and commercialisation costs and future profits shared equally |
What Happened | Sanofi and Regeneron expanded their longstanding immunology alliance to include four next-generation antibody programmes. |
Why It Matters | The transaction extends one of biopharma's most established immunology partnerships into additional long-acting programmes intended to build on the companies' experience with Dupixent. |
Strategic Rationale | Sanofi and Regeneron are combining their immunology development capabilities to create longer-acting and potentially differentiated therapies across inflammatory diseases. |
Potential Impact | Successful programmes could expand the companies' presence across major immunology indications and create successors or complements to existing therapies. |
Key Takeaway | Sanofi and Regeneron have expanded their immunology alliance in a transaction worth up to $8 billion. |
What to Watch | Clinical progression of REGN20423, development of the IL-4xIL-13 bispecific and disclosure of the remaining programmes. |
Primary Source | Regeneron |
Relevant Date | 1 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare